AOP - progressing to human trials...this could be very big...At the beginning of February, Apollo Life Sciences announced that the final report confirms the success of its oral insulin in Phase 1 toxicology trials.
Apollo's oral insulin consists of Oradel, loaded with generic insulin.
The treatment proved safe at both low and high doses.
The toxicology study was designed to test the safety of Apollo's oral insulin for people with diabetes.
The key findings are that Oradel insulin caused no toxic effects or treatment-related changes in body weights, food consumption, blood analysis, urinalysis, gross necroscopy or histopathology.
"These favourable results provide strong supporting safety data for taking our oral insulin to Phase 1 human clinical trials, which we expect to undertake in the coming months," Dr Russell-Jones said.
Diabetes is responsible for approximately four million deaths worldwide every year.
It is estimated that there are now 246 million people with diabetes, growing to 380 million by 2025.
"Our innovative oral insulin could mean the end of needles for many people with diabetes.
Some need up to five insulin shots a day to manage their condition, said Dr Russell-Jones.
"It is only a matter of time before we enter the marketplace with our insulin in a tablet, and we believe that most people prefer to take a tablet instead of an injection," he added.
Long term hold I suggest, and bargain entry at these post "correction" prices (40c presently)
AOP Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
